These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 33101604)
1. Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19. Ab Ghani NS; Emrizal R; Makmur H; Firdaus-Raih M Comput Struct Biotechnol J; 2020; 18():2931-2944. PubMed ID: 33101604 [TBL] [Abstract][Full Text] [Related]
2. Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning. Ab Ghani NS; Ramlan EI; Firdaus-Raih M Nucleic Acids Res; 2019 Jul; 47(W1):W350-W356. PubMed ID: 31106379 [TBL] [Abstract][Full Text] [Related]
6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
7. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease. Cashman DP Med Hypotheses; 2020 Nov; 144():110027. PubMed ID: 32758873 [TBL] [Abstract][Full Text] [Related]
8. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Husain A; Byrareddy SN Chem Biol Interact; 2020 Nov; 331():109282. PubMed ID: 33031791 [TBL] [Abstract][Full Text] [Related]
9. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease. Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685 [TBL] [Abstract][Full Text] [Related]
10. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381 [TBL] [Abstract][Full Text] [Related]
11. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935 [TBL] [Abstract][Full Text] [Related]
12. Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages. Singh N; Decroly E; Khatib AM; Villoutreix BO Eur J Pharm Sci; 2020 Oct; 153():105495. PubMed ID: 32730844 [TBL] [Abstract][Full Text] [Related]
13. Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction. Peng L; Tian X; Shen L; Kuang M; Li T; Tian G; Yang J; Zhou L Front Genet; 2020; 11():577387. PubMed ID: 33193695 [TBL] [Abstract][Full Text] [Related]
14. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
15. Shape-based Machine Learning Models for the Potential Novel COVID-19 Protease Inhibitors Assisted by Molecular Dynamics Simulation. Nayarisseri A; Khandelwal R; Madhavi M; Selvaraj C; Panwar U; Sharma K; Hussain T; Singh SK Curr Top Med Chem; 2020; 20(24):2146-2167. PubMed ID: 32621718 [TBL] [Abstract][Full Text] [Related]
16. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data. Chakraborti S; Bheemireddy S; Srinivasan N Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772 [TBL] [Abstract][Full Text] [Related]
17. A Computational Pipeline to Identify and Characterize Binding Sites and Interacting Chemotypes in SARS-CoV-2. Sandholtz SH; Drocco JA; Zemla AT; Torres MW; Silva MS; Allen JE ACS Omega; 2023 Jun; 8(24):21871-21884. PubMed ID: 37309388 [TBL] [Abstract][Full Text] [Related]
18. A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research. Zahoránszky-Kőhalmi G; Siramshetty VB; Kumar P; Gurumurthy M; Grillo B; Mathew B; Metaxatos D; Backus M; Mierzwa T; Simon R; Grishagin I; Brovold L; Mathé EA; Hall MD; Michael SG; Godfrey AG; Mestres J; Jensen LJ; Oprea TI bioRxiv; 2020 Nov; ():. PubMed ID: 33173863 [TBL] [Abstract][Full Text] [Related]
19. Shorter incubation period is associated with severe disease progression in patients with COVID-19. Lai C; Yu R; Wang M; Xian W; Zhao X; Tang Q; Chen R; Zhou X; Li X; Li Z; Li Z; Deng G; Wang F Virulence; 2020 Dec; 11(1):1443-1452. PubMed ID: 33108255 [TBL] [Abstract][Full Text] [Related]
20. Biochemical parameters and pathogenesis of SARS-CoV-2 infection in vital organs: COVID-19 outbreak in Iran. Mirmohammadi S; Kianmehr A; Arefi M; Mahrooz A New Microbes New Infect; 2020 Nov; 38():100792. PubMed ID: 33101694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]